Skip to content
Buy This GLP
← Research
Evidence

Tirzepatide and Heart Outcomes in Type 2 Diabetes

In adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide met the prespecified noninferiority margin versus dulaglutide for cardiovascular death, heart attack or stroke.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team9 min read
Cardiovascular death, heart attack or stroke0.921.00better, if cleared1.05margin0.831.01

The evidence on heart attacks and other cardiovascular outcomes helps distinguish event rates from changes in risk factors. Among 13,165 participants included in the primary analysis, cardiovascular death, heart attack or stroke occurred in 12.2% on tirzepatide and 13.1% on dulaglutide [1]. The hazard ratio was 0.92 (95.3% CI 0.83 to 1.01). The trial did not establish that tirzepatide was superior.

What the outcomes trial asked

It was an active-comparator, double-blind noninferiority trial. Participants were randomized 1:1 to weekly tirzepatide, titrated to as much as 15 mg, or to dulaglutide 1.5 mg. Of 13,299 randomized participants, 134 did not meet the inclusion criteria and were excluded from the primary analysis. The paper identifies that dulaglutide dose as the one already shown to reduce cardiovascular events. Mean age was 64.1, mean HbA1c 8.4%, and mean diabetes duration 14.7 years.

The design decides what the result can say. A noninferiority trial asks whether the new drug is not meaningfully worse. The margin was 1.05 for the upper confidence limit. Superiority required that limit to fall below 1.00. Noninferiority was met at P=0.003. Superiority was not, at P=0.09.

What happened to the heart itself

An imaging substudy scanned patients with obesity-related heart failure with preserved ejection fraction, before and after a year [2]. Left ventricular mass fell 11 g against placebo, 95% CI −19 to −4, P=0.004. Paracardiac fat fell 45 mL, 95% CI −69 to −22, P<0.001.

Two limits travel with those figures. Of 175 patients scanned, 106 completed a usable second scan, leaving arms of 50 and 56. And the change in left ventricular mass correlated with the change in body weight, P<0.02. The heart may have remodeled because of the drug, or because of the weight the drug removed, and one active arm cannot separate them.

These are structural measurements rather than events. Nobody in the substudy was shown to be hospitalized less often, because it did not measure that. The authors say the changes may contribute to the parent trial’s event reduction, and that verb is theirs.

The risk factors, counted as a package

A post hoc analysis of SURMOUNT-1 through SURMOUNT-4 asked how often three targets arrive together [3]. The targets were a weight-loss threshold, a systolic pressure fall of at least 5 mmHg, and non-HDL cholesterol below 130 mg/dL.

At the 15% weight threshold, 22% to 34% of treated participants hit all three, against 1% to 3% on placebo. At 5% it was 32% to 38% against 2% to 8%. Every comparison reached p<0.001. The ranges span four trials in different populations.

In the research on blood pressure, a change in systolic pressure can be reported on its own. Here, a participant could improve on one measure and still miss the combined endpoint by staying above the cholesterol threshold.

How the results apply

The three reports cover different populations and outcomes. SURPASS-CVOT enrolled adults with type 2 diabetes and established atherosclerotic cardiovascular disease. SUMMIT imaging enrolled people with obesity-related heart failure, and the SURMOUNT analysis retrospectively combined measurements of weight, blood pressure and cholesterol. The event comparison cannot establish the benefit for someone taking tirzepatide solely for weight loss.

142 sellers here publish a price for both molecules by injection, read November 2026. Across those, tirzepatide runs a median of $70 more a month, with 136 charging more for it and 2 charging less. Whether that gap is worth paying is answered on its own evidence, and this trial is one input rather than the answer.

Frequently asked

Is tirzepatide good for your heart?
In the trial population with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide met the prespecified noninferiority margin versus dulaglutide. Cardiovascular death, heart attack or stroke occurred in 12.2% and 13.1%, respectively.
Did it beat the older drug?
No. It met noninferiority at P=0.003 and missed superiority at P=0.09, with an upper confidence bound of 1.01, just above the 1.00 that superiority required.
Does it change the heart itself?
In an imaging substudy, left ventricular mass fell 11 g against placebo and paracardiac fat fell 45 mL. Those are structural measurements, and the mass change tracked the weight change at P<0.02.
Does it fix blood pressure and cholesterol too?
In a post hoc analysis of four trials, 22% to 34% of treated participants hit a 15% weight threshold, a 5 mmHg systolic fall and non-HDL cholesterol under 130 mg/dL at once, against 1% to 3% on placebo.
Does this apply to someone buying for weight loss?
Not directly. The outcomes trial enrolled people averaging 14.7 years of type 2 diabetes with established atherosclerotic disease, which is not the person buying a GLP-1 for weight.

Sources

  1. [1] Nicholls SJ, et al. (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England Journal of Medicine. PMID 41406444
  2. [2] Kramer CM, et al. (2025). Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy Journal of the American College of Cardiology. PMID 39566869
  3. [3] Sattar N, et al. (2026). Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials PLOS ONE. PMID 42594122

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence